The Zhitong Finance App learned that Lyon released a research report stating that the target price of Cinda Biotech (01801) was raised from HK$139.9 to HK$146.1, maintaining a “outperforming the market” rating. According to Lyon, Cinda Biotech's product sales revenue in the first half of this year increased 56.7% year-on-year, and net profit was better than market expectations. The Group's 2027 sales target set in 2022 is highly visible, and the mid-term plan has been updated to target revenue of 35 billion to 40 billion yuan by 2030, and to reach the profit level of top pharmaceutical companies. Lyon continues to regard Cinda Biotech as one of the preferred stocks in the Chinese biotech industry.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.